<code id='1094E4AB5E'></code><style id='1094E4AB5E'></style>
    • <acronym id='1094E4AB5E'></acronym>
      <center id='1094E4AB5E'><center id='1094E4AB5E'><tfoot id='1094E4AB5E'></tfoot></center><abbr id='1094E4AB5E'><dir id='1094E4AB5E'><tfoot id='1094E4AB5E'></tfoot><noframes id='1094E4AB5E'>

    • <optgroup id='1094E4AB5E'><strike id='1094E4AB5E'><sup id='1094E4AB5E'></sup></strike><code id='1094E4AB5E'></code></optgroup>
        1. <b id='1094E4AB5E'><label id='1094E4AB5E'><select id='1094E4AB5E'><dt id='1094E4AB5E'><span id='1094E4AB5E'></span></dt></select></label></b><u id='1094E4AB5E'></u>
          <i id='1094E4AB5E'><strike id='1094E4AB5E'><tt id='1094E4AB5E'><pre id='1094E4AB5E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:57145
          A medical insurance document printed with the words "COPAY," "DEDUCTIBLE," "COINSURANCE," "NON-COVERED," next to a pen — coverage from STAT
          Adobe

          WASHINGTON — Insurers will have to count drug copay coupons toward deductibles and patient spending caps in most cases, after a Biden move in federal court on Tuesday.

          Drug companies use copay coupons to help patients cover the cost of their drugs.

          advertisement

          Before now, when drug companies helped patients pay their share of drug costs, insurers often didn’t count that assistance toward deductibles and out-of-pocket limits. In insurance jargon, this tactic is called a copay accumulator. Previously, the practice was only allowed when drug companies give coinsurance assistance for brand drugs with generic competition. The Trump administration let insurers use the tactic when cheaper generics were not available.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Shionogi licenses Pompe disease therapy from Maze Therapeutics
          Shionogi licenses Pompe disease therapy from Maze Therapeutics

          MazeTherapeuticsCEOJasonColomaCourtesyAfterseeingitslastdealgobustinthefaceofregulatoryscrutiny,Maze

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          How to improve immunocompromised access to mAb treatments

          Monoclonalantibodiesfightagroupofcoronaviruscellsina3Drendering.AdobeAstheU.S.grappleswiththelasting